Table 1.
Study Demographics
| All Subjects (n=38) |
Suprachoroidal CLS-TA + Intravitreal Aflibercept - Combination Arm (n=21) |
Intravitreal Aflibercept Only - Monotherapy Arm (n=17) |
P-value | |
|---|---|---|---|---|
| Age (years ± SD) | 65.7 ± 12.1 | 67.1 ± 9.0 | 64.1 ± 15.3 | 0.451 |
| Gender (male / female) | 20 / 18 | 13 / 8 | 7 / 10 | 0.343 |
| Race (CH / AA / AI) | 33 / 4 / 1 | 19 / 2 / 0 | 14 / 2 / 1 | 0.509 |
| Baseline VA (ETDRS letters) | 50.3 + 14.9 | 50.2 + 17.1 | 50.5 + 12.5 | 0.952 |
| Baseline CT (mean ± SE µm) | ||||
| VCT | 219.9 ± 14.2 | 234.9 ± 24.3 | 208.5 ± 15.0 | 0.369 |
| SCT | 248.9 ± 14.9 | 263.3 ± 25.4 | 233.5 ± 14.8 | 0.327 |
| TCT | 256.3 ± 15.0 | 272.9 ± 25.6 | 238.7 ± 14.5 | 0.262 |
| SCS Present (%) | 15 (39.5%) | 9 (42.9%) | 6 (35.3%) | 0.744 |
1
Abbreviations: CH, Caucasian/Hispanic; AA, African American; AI, American Indian; VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; VCT, vascular choroidal thickness; SCT, stromal choroidal thickness; TCT, total choroidal thickness; n, number; SD, standard deviation; SE, standard error; SCS, suprachoroidal space.